January 2, 2013
In December 2012, we hosted a roundtable discussion focused on our activities and progress with our conjugate platform to deliver RNAi therapeutics subcutaneously. The roundtable included a review of our two leading conjugate programs: ALN-TTRsc for the treatment of transthyretin mediated amyloidosis, and ALN-AT3 for the treatment of hemophilia and other bleeding disorders.
Listen to the replay View the presentation (254 KB PDF)
December 10, 2012
Today we are presenting new data from our ALN-AT3 program for the treatment of hemophilia and other bleeding disorders at the 54th American Society of Hematology (ASH) Annual Meeting in Atlanta. ALN-AT3 comprises part of our “Alnylam 5×15™” strategy, which is aimed at bringing innovative medicines to patients, with a focus on RNAi therapeutics toward genetically defined targets for diseases with very high unmet medical need.
View our poster (2.3 MB PDF) Read our press releaseNovember 1, 2012
At the 8th Annual Meeting of the Oligonucleotide Therapeutics Society, held in Boston October 28-31, 2012, we presented exciting data covering several of the company’s therapeutic programs and delivery platforms.
THERAPEUTIC PROGRAMS
Therapeutic research highlighted recent clinical and pre-clinical work from our programs in transthyretin-mediated amyloidosis (TTR), hemophilia, hypercholesterolemia, and liver cancer. Click here for presentations.
August 6, 2012
New data from our conjugate delivery platform was presented at the XX International Roundtable on Nucleosides, Nucleotides and Nucleic Acids held in August 2012. This delivery platform enables subcutaneous dose administration of RNAi therapeutics with a very wide therapeutic index. We are integrating this approach in our ‘Alnylam 5×15’ efforts with ALN-TTRsc for the treatment of ATTR, ALN-AT3 for the treatment of hemophilia, and potentially future programs.
View our presentation (1.6 MB PDF)
Read our press release (PDF)July 11, 2012
At the World Federation of Hemophilia World Congress in July 2012, scientists presented pre-clinical data with ALN-AT3, our development candidate targeting antithrombin (AT) for the treatment of hemophilia. The new data demonstrate potent and durable AT knockdown with subcutaneous administration of ALN-AT3. ALN-AT3 was shown to improve thrombin generation in hemophilia animal models.
View our poster (slide format) (774 KB PDF) View our poster (3.3 MB PDF) View our releaseDecember 13, 2011
In December 2011, our scientists presented multiple posters and presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, CA. We shared data from two programs within our “Alnylam 5×15” product pipeline, including pre-clinical data from ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia,…
View the refractory anemia presentation (680 KB PPT) View the hemophilia poster (1.88 MB PDF) View the beta-thalassemia poster (112 KB PDF) View the erythropoiesis poster (435 KB PDF) Read our press releaseSeptember 8, 2011
We have launched our fourth program as part of our Alnylam 5×15 product development strategy. ALN-APC is an RNAi therapeutic for the treatment of hemophilia, and as with our other Alnylam 5×15 programs, targets protein C, a genetically defined target, and will utilize Alnylam’s existing delivery platform.
Read our press release Listen to our CMO discuss the hemophilia program (13.3MB mp3) View the slides (1.5MB PPT)July 24, 2011
In January 2011, we were very excited to launch our Alnylam 5×15™RNAi therapeutic product strategy. Alnylam 5×15 was established to focus on the development and commercialization of novel RNAi therapeutics addressing genetically defined diseases with major unmet medical need.
Read our press release Listen to our CEO discuss our 5×15 Strategy (4.7MB MP3) Rare Disease Day podcast (7.2MB MP3)
